Comparison of the Effects of Pioglitazone vs. Placebo When Given in Addition to Standard Insulin Treatment in Patients With Type 2 Diabetes Mellitus and Renal Failure.

Trial Profile

Comparison of the Effects of Pioglitazone vs. Placebo When Given in Addition to Standard Insulin Treatment in Patients With Type 2 Diabetes Mellitus and Renal Failure.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2013

At a glance

  • Drugs Pioglitazone (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms PIOren
  • Sponsors Takeda Pharma
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Apr 2012 Planned number of patients changed from 40 to 100 as reported by European Clinical Trials Database record.
    • 21 Apr 2012 New source identified and integrated (European Clinical Trials Database record EudraCT2007-006744-21).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top